Vical to present Congenital CMV vaccine candidate
Vaxfectin is the company’s new proprietary cationic lipid-based adjuvant. It has been used with Vical’s congenital cyclomegaovirus vaccine candidate, CyMVectin.
“A vaccine to prevent birth defects caused by cytomegalovirus is a public health priority," Virginia Commonwealth University Emeritus Professor in the Department of Microbiology and Immunology Stuart Adler said. "Accumulating evidence suggests that induction of antibodies that block viral entry into a broad range of cell types is an important determinant of vaccine efficacy. A gB DNA vaccine performs well in this regard, when compared with responses induced by natural infection. In addition, the simplicity of a single subunit delivered by DNA immunization is highly attractive compared with more complicated vaccines in development.”
The studies show that encoding gB vaccines gave epithelial and fibroblast entry with neutralizing elements similar to human sera from patients who acquired CMV infections naturally. This suggests that CyMVectin could potentially encourage antibodies to battle a wide range of virus cells.
"We believe that induction of both fibroblast and epithelial entry neutralizing antibodies is essential for providing protection against CMV," Vical's Vice President of Vaccine Research Larry Smith said. "These findings support further development of CyMVectin for prevention of congenital CMV infections."